Humana Inc.
NYSE:HUMMedical - Healthcare Plans
+$0.70 today
- Market cap
- $46.32B
- Beta
- 0.77
- P/E (TTM)
- 38.6
- EPS (TTM)
- $9.39
- Dividend yield
- 0.98%
Volume 4.06M
Average 1.72M
HUM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Humana Inc.NYSE: HUM
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $187M fell 8.3% year over year, ahead of the -12.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -8.3% holds above the trailing-twelve-month pace of -12.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 824M USD
- Year-over-year change
- -14.9%
- 4-year CAGR
- +3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 824M | -14.9% |
| FY2024 | 2024-12-31 | 968M | +5.6% |
| FY2023 | 2023-12-31 | 917M | +8.5% |
| FY2022 | 2022-12-31 | 845M | +18.5% |
| FY2021 | 2021-12-31 | 713M | — |
Depreciation & Amortization vs competitors
How HUM compares with its peers on the latest reported figures
- HUM's LTM Sep 2026 depreciation & amortization of $763M is the 6th largest of the 9 companies compared; the peer median is $1.37B.
- Its year-over-year change of -12.3% is the 8th highest of 9, against a peer median of -1.6%.
- Depreciation & amortization amounts to 0.5% of revenue for HUM, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $4.26B | -0.6% | +8.7% | 0.9% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Sep 2026 | $1.49B | -3.2% | -2.6% | 0.7% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $763M | -12.3% | -0.8% | 0.5% | |
| LTM Sep 2026 | $161M | -19.1% | +3.5% | 0.4% | |
| LTM Mar 2026 | $30.72M | +7.2% | +21.8% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| Peer median (excluding HUM) | $1.37B | -1.6% | +3.2% | 0.7% | |
Competitors are the stored peer set for HUM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.93B | 2.8B | 2.49B | 1.21B | 1.2B |
| Depreciation & Amortization | 713M | 845M | 917M | 968M | 824M |
| Deferred Income Tax | 15M | (100M) | (167M) | (192M) | 75M |
| Stock-Based Compensation | 180M | 216M | 175M | 207M | 241M |
| Change in Working Capital | (556M) | 534M | 81M | 154M | (1.8B) |
| Accounts Receivables | (280M) | (54M) | (337M) | (669M) | (570M) |
| Inventory | 0 | 0 | (364M) | 0 | 0 |
| Accounts Payables | 104M | 975M | 915M | 199M | (472M) |
| Other Working Capital | (380M) | (387M) | (133M) | 624M | (755M) |
| Other Non-Cash Items | (1.02B) | 290M | 486M | 615M | 375M |
| Operating Cash Flow | 2.26B | 4.59B | 3.98B | 2.97B | 921M |
| Capital Expenditures | (1.34B) | (1.14B) | (1B) | (575M) | (546M) |
| Acquisitions (Net) | (4.19B) | 2.36B | (233M) | (89M) | (81M) |
| Purchases of Investments | (7.2B) | (6.05B) | (7.55B) | (8.19B) | (6.44B) |
| Sales of Investments | 6.14B | 3.8B | 5.09B | 6.36B | 9.42B |
| Other Investing Activities | 26M | 17M | 210M | (461M) | (82M) |
| Investing Cash Flow | (6.56B) | (1.01B) | (3.49B) | (2.95B) | 2.27B |
| Debt Repayment | 3.76B | (1.39B) | 423M | 218M | 431M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (79M) | (2.1B) | (1.57B) | (817M) | (151M) |
| Dividends Paid | (354M) | (392M) | (431M) | (431M) | (430M) |
| Other Financing Activities | (310M) | 1.97B | 725M | (1.46B) | (1.07B) |
| Financing Cash Flow | 3.02B | (1.91B) | (856M) | (2.49B) | (1.22B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.28B) | 1.67B | (367M) | (2.47B) | 1.98B |
| Free Cash Flow | 920M | 3.45B | 2.98B | 2.39B | 375M |
Humana Inc.
NYSE:HUM
Intrinsic Alpha fair value
Locked
Current Price
$385.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.